Knockout Tested Mouse Monoclonal E2F1 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 21 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human E2F1.
View Alternative Names
RBBP3, E2F1, Transcription factor E2F1, E2F-1, PBR3, Retinoblastoma-associated protein 1, Retinoblastoma-binding protein 3, pRB-binding protein E2F-1, RBAP-1, RBBP-3
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-E2F1 antibody [KH95] (AB4070)
ab4070 staining human tonsil by IHC-P.
- WB
Lab
Western blot - Anti-E2F1 antibody [KH95] (AB4070)
Western blot : Anti-E2F1 antibody [KH95] (ab4070) staining at 1/500 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in magenta. In Western blot, ab4070 was shown to bind specifically to E2F1. A band was observed at 47 kDa in wild-type HCT 116 cell lysates with no signal observed at this size in E2F1 knockout cell line. To generate this image, wild-type and E2F1 knockout HCT 116 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-E2F1 antibody [KH95] (ab4070) at 1/500 dilution
Lane 1:
Wild-type HCT 116 cell lysate at 20 µg
Lane 2:
E2F1 knockout HCT 116 cell lysate at 20 µg
Lane 3:
Wild-type HEK-293 ab259780 cell lysate at 20 µg
Lane 4:
E2F1 knockout HEK-293 <a href='/en-us/products/cell-lines/human-e2f1-knockout-hek-293-cell-line-ab269502'>ab269502</a> cell lysate at 20 µg
Secondary
All lanes:
Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution
false
- WB
Lab
Western blot - Anti-E2F1 antibody [KH95] (AB4070)
Lanes 1 - 5 : Merged signal (red and green). Green - ab4070 observed at 55 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.
ab4070 was shown to react with E2F1 in wild-type HEK-293 cells in Western blot with loss of signal observed in E2F1 knockout sample. Wild-type HEK-293 and E2F1 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab4070 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4°C at a 1 in 500 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-E2F1 antibody [KH95] (ab4070) at 1/500 dilution
Lane 1:
Wild-type HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg
Lane 2:
E2F1 knockout HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg
Lane 2:
Western blot - Human E2F1 knockout HEK-293 cell line (<a href='/en-us/products/cell-lines/human-e2f1-knockout-hek-293-cell-line-ab269502'>ab269502</a>)
Lane 3:
Hep G2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 20 µg
Lane 4:
U-2 OS (Human bone osteosarcoma epithelial cell line) whole cell lysate at 20 µg
Lane 5:
HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg
Predicted band size: 47 kDa
Observed band size: 55 kDa
false
- WB
CiteAb
Western blot - Anti-E2F1 antibody [KH95] (AB4070)
Western Blotting using Anti-E2F1 antibody [KH95]Anti-E2F1 antibody [KH95], ab4070. Publication image from Meng, X. et al., 2020, Nat Commun, 32001707. Legend direct from paper.
BIP-MPC-NP restrains E2F1-mediated DNA damage repair modules via the inhibitory effect of TTP.a E2F1 binding sites within a region spanning ± 3 kb around TSS in the whole genome. b The signal peaks located in the promoter regions of CHEK1, CHEK2, RAD50, RAD51 and TP53 in E2F1 ChIP-seq data and the binding sites of E2F1 were predicted on JASPAR datasets. The agarose gel electrophoresis displayed the enrichments of E2F1 in the promoter regions of CHEK1, CHEK2, RAD50, RAD51 and TP53 of LN229R. c The luciferase reporter assay displayed the E2F1 transcriptional activity in the promoter regions of CHEK1, CHEK2, RAD50, RAD51 and TP53 in LN229R (n = 3). d The TTP protein expression and E2F1 mRNA expression in LN229R, U87MGR and HG9R treated with MPC-NP or BIP-MPC-NP. e The inhibitory effect of TTP on wild-type or mutant-type ARE motifs within the E2F1 mRNA 3′-UTR in LN229R cells with MPC-NP or BIP-MPC-NP treatments (n = 3). The error bars in c and e represent the S.D. of three measurements. P value is determined by Student’s t-test. Significant results are presented as NS non-significant, *P < 0.05, **P < 0.01, ***P < 0.001.
false
- WB
CiteAb
Western blot - Anti-E2F1 antibody [KH95] (AB4070)
Western Blotting using Anti-E2F1 antibody [KH95]Anti-E2F1 antibody [KH95], ab4070. Publication image from Kanakkanthara, A. et al., 2019, Nat Commun, 31604914. Legend direct from paper.
ZC3H18 binds the BRCA1 promoter and inhibits E2F1 binding. a Schematic of the BRCA1 proximal promoter with E2FA and E2FB sites indicated. Nucleotide sequences of the DNA probes used in the electrophoretic mobility shift assays (EMSA). E2FA and E2FB mutation sites are indicated in open rectangles. b EMSA with purified recombinant SFB-ZC3H18 using BRCA1 promoter probe with wild-type sequence (E2FA/BWT) or mutations in the E2FA site (E2FδA), the E2FB site (E2FδB), or both E2F sites (E2FδA/B). A probe with randomly shuffled sequences was used as negative control. For supershift assays, an anti-S-Tag monoclonal antibody, which binds the SFB tag in SFB-ZC3H18, was used. c, d ZC3H18 and E2F4 co-occupy the endogenous BRCA1 promoter. Sequential ChiP (ChIP-Re-ChIP) assays in OVCAR-8 cells using anti-ZC3H18 antibody for primary ChIP and anti-E2F4 antibody for secondary ChIP (c) and using anti-E2F4 antibody for primary ChIP and anti-ZC3H18 antibody for secondary ChIP (d). e EMSA with purified recombinant SFB-ZC3H18 and SFB-E2F1 using BRCA1 promoter probe with mutated E2FB site (E2FδB). f EMSA with purified SFB-E2F4 and SFB-E2F1 using BRCA1 promoter probe with mutated E2FA site (E2FδA). The images of EMSA in b, e, and f are representative of three independent experiments that gave similar results. Data in c and d are means ± SEM of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t-test
false
- WB
CiteAb
Western blot - Anti-E2F1 antibody [KH95] (AB4070)
Western Blotting using Anti-E2F1 antibody [KH95]Anti-E2F1 antibody [KH95], ab4070. Publication image from Kanakkanthara, A. et al., 2019, Nat Commun, 31604914. Legend direct from paper.
ZC3H18 occupies the BRCA1 promoter and regulates E2F1. a OVCAR-8, OVCAR-5, and PEA1 cells were processed for ChIP assays using anti-ZC3H18 or IgG control antibodies and primers specific for the BRCA1 promoter. b OVCAR-8 cells transiently expressing SFB-ZC3H18 were processed for ChIP assays using FLAG or IgG control antibodies. c, d ChIP assays showing increased occupancy of E2F1 on the BRCA1 promoter when ZC3H18 is depleted. OVCAR-8 (c) and PEA1 (d) cells transfected with control luciferase (Luc) or ZC3H18 siRNAs (siZC3) were processed for ChIP using anti-E2F1 or IgG control antibodies 48 h after transfection. e E2F1 depletion does not affect BRCA1 levels. OVCAR-8 cells were transfected with control luciferase (Luc) or two independent E2F1 siRNAs and analyzed for BRCA1, E2F1, and HSP90 levels by immunoblotting 48 h later. f DNMT1 occupancy on the BRCA1 promoter requires E2F1. OVCAR-8 cells transfected with Luc, E2F1, or ZC3H18 siRNA with our without E2F1 siRNAs were processed for ChIP with DNMT1 or control IgG antibodies 48 h after transfection. g Depletion of E2F1 restores BRCA1 expression when ZC3H18 is depleted. OVCAR-8 cells transfected with Luc, E2F1, or ZC3H18 siRNAs with our without E2F1 siRNAs were analyzed for BRCA1 mRNA levels by qRT-PCR. BRCA1 mRNA levels were normalized to GAPDH mRNA levels. Data in a–g are means ± SEM from three independent experiments. **p < 0.01, ***p < 0.001, unpaired Student’s t-test. Representative immunoblots in e are provided from three independent experiments. Unprocessed blots are provided in Source data file
false
Reactivity data
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
E2F1 plays a significant role in cell growth regulation and apoptosis. E2F1 functions within a complex often forming heterodimers with DP proteins. This combination enhances its ability to bind DNA and activate transcription of genes necessary for DNA replication and cell cycle progression. E2F1 also participates in the control of apoptosis by regulating the expression of pro-apoptotic genes balancing cell proliferation and death.
Pathways
E2F1 is deeply embedded in cell cycle regulatory pathways and the p53 signaling pathway. It closely interacts with proteins like RB (Retinoblastoma protein) and p53. RB protein regulates E2F1 activity by controlling its release while p53 helps in mediating the cell's response to DNA damage potentially leading to either cell cycle arrest or apoptosis. These interactions highlight E2F1's role in maintaining cellular homeostasis.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (21)
Recent publications for all applications. Explore the full list and refine your search
iScience 27:110462 PubMed39104405
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cancer gene therapy 30:1007-1017 PubMed36973424
2023
Applications
Unspecified application
Species
Unspecified reactive species
Toxicology research 11:831-840 PubMed36337239
2022
Applications
Unspecified application
Species
Unspecified reactive species
Disease markers 2022:6329097 PubMed36016851
2022
Applications
Unspecified application
Species
Unspecified reactive species
Translational oncology 18:101304 PubMed35144091
2022
Applications
Unspecified application
Species
Unspecified reactive species
Disease markers 2021:6256369 PubMed34616498
2021
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 49:10419-10430 PubMed34520549
2021
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 22:531 PubMed34079590
2021
Applications
Unspecified application
Species
Unspecified reactive species
Journal of experimental & clinical cancer research 39:216 PubMed33054826
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 11:594 PubMed32001707
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com